Ardent Health Partners, Inc. (ARDT)vsEli Lilly and Company (LLY)
ARDT
Ardent Health Partners, Inc.
$9.76
+1.35%
HEALTHCARE · Cap: $1.38B
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 931% more annual revenue ($65.18B vs $6.32B). LLY leads profitability with a 31.7% profit margin vs 2.1%. ARDT trades at a lower P/E of 10.0x. LLY earns a higher WallStSmart Score of 78/100 (B+).
ARDT
Hold43
out of 100
Grade: D
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
Smaller company, higher risk/reward
2.1% margin — thin
Elevated debt levels
Revenue declined 0.1%
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ARDT
The strongest argument for ARDT centers on P/E Ratio, Price/Book.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : ARDT
The primary concerns for ARDT are Market Cap, Profit Margin, Debt/Equity. Debt-to-equity of 1.84 is elevated, increasing financial risk. Thin 2.1% margins leave little buffer for downturns.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
ARDT profiles as a value stock while LLY is a growth play — different risk/reward profiles.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 43/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ardent Health Partners, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Ardent Health Partners, Inc., headquartered in Nashville, Tennessee, is a premier healthcare organization focused on delivering high-quality, patient-centered care through a comprehensive network of hospitals and outpatient facilities. Renowned for its extensive portfolio of acute care hospitals, Ardent is dedicated to innovating healthcare solutions that meet the diverse and evolving needs of communities. With a solid financial structure and a strategic vision for growth, the company is well-positioned to enhance access to healthcare and improve patient outcomes in a complex and dynamic industry landscape.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?